Ultragenyx Pharmaceutical (RARE) vs Zenas BioPharma (ZBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zenas BioPharma (ZBIO) has outperformed Ultragenyx Pharmaceutical (RARE) over the past year, losing 33.4% versus a loss of 50.9%. Ultragenyx Pharmaceutical is the larger company by market cap ($1.68 billion vs $1.62 billion), about 1.0 times the size, while Zenas BioPharma is growing revenue faster (+100.0% vs +20.2%). Ultragenyx Pharmaceutical converts more of its revenue into profit, with a net margin of -85.4% versus -3777.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RARE | ZBIO |
|---|---|---|
| Share price | $16.48 | $23.85 |
| Market cap | $1.68B | $1.62B |
| 1-day change | -4.30% | -4.75% |
| YTD return | -28.35% | -34.32% |
| 1-year return | -50.94% | -33.38% |
| 5-year return | -78.45% | — |
| Forward P/E | 11.50 | — |
| EPS (TTM) | $-5.17 | $-9.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $673.00M | $10.00M |
| Revenue growth (YoY) | +20.18% | +100.00% |
| Net income (latest FY) | $-575.00M | $-377.74M |
| Operating margin | -79.49% | -3830.57% |
| Net margin | -85.44% | -3777.37% |
| 52-week high | $39.89 | $44.60 |
| 52-week low | $12.73 | $13.50 |
| Distance from 52-week high | -58.69% | -46.52% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +50.49% | +100.75% |
| Average volume | 4.69M | 593.08K |
| Shares outstanding | 101.92M | 67.82M |
| Employees | 1,371 | 167 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZBIO has outperformed RARE by 17.6 percentage points over the past year.
- Ultragenyx Pharmaceutical is more profitable, keeping -85.4 cents of every revenue dollar as net income versus -3777.4 cents for Zenas BioPharma.
- Zenas BioPharma grew revenue faster in its latest fiscal year (+100.00% vs +20.18%).
About Ultragenyx Pharmaceutical
RARE stock →Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,371 employees
About Zenas BioPharma
ZBIO stock →Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc?RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus.
Health Care · Biotechnology: Pharmaceutical Preparations · 167 employees
RARE vs ZBIO FAQ
Which is bigger, Ultragenyx Pharmaceutical or Zenas BioPharma?
Ultragenyx Pharmaceutical (RARE) is larger, with a market capitalization of $1.68B compared with $1.62B for Zenas BioPharma (ZBIO).
Which stock has performed better over the past year, RARE or ZBIO?
ZBIO returned -33.38% over the past 12 months, compared with -50.94% for RARE (price return, excluding dividends). Past performance does not predict future results.
Are Ultragenyx Pharmaceutical and Zenas BioPharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.